Advances In The Management Of Chronic Lymphocytic Leukemia And Other B-Cell Lymphomas

Advances In The Management Of Chronic Lymphocytic Leukemia And Other B-Cell Lymphomas

On-Demand Webcast

This webcast is based on live proceedings from a Friday Satellite Symposium preceding the 59th ASH Annual Meeting and Exposition.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Faculty

Chadi Nabhan, MD, MBA, FACP
Vice President and Chief Medical Officer
Cardinal Health Specialty Solutions
Chicago, Illinois

Matthew J. Matasar, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony R. Mato, MD
Center for Chronic Lymphocytic Leukemia
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Val R. Adams, PharmD, BCOP, FCCP
Associate Professor
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Intended Learners

Oncologists, hematologists, hematologists/oncologists and other members of the multidisciplinary oncology healthcare team.

Learning Objectives

After completing this activity, participants should be able to

  • Summarize the latest evidence pertaining to new and emerging therapeutic options for the management of CLL, including outcomes within special populations
  • Describe newer therapeutic approaches for the treatment of indolent B-cell lymphomas
  • Outline clinical updates within the management of aggressive B-cell lymphoma, including treatment naive, relapsed/refractory, and double hit lymphoma
  • Implement treatment strategies for CLL and other B-cell lymphomas that are informed by the latest available evidence and consider individual patient profiles
Activity Overview

This on-demand webcast is available with synchronized slides and video.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Release Date:  December 22, 2017
Expiration Date: December 22, 2018
Estimated time to complete: 3.25 hours

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians

CME

The University of Cincinnati designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee

The planning committee comprises Val R. Adams, PharmD, BCOP, FCCP, Chadi Nabhan, MD, MBA, FACP, Matthew J. Matasar, MD, Anthony R. Mato, MD, Barbara Rogers, CRNP, MN, AOCN, ANP-BC; Donna Brophy, Jennifer Browne, Celeste Callazo, MD, Mary Johnson, Mike Kearney, Randy Robbin, and John Savage, NACCME; and Barbara Forney, Ricker Ricer, MD, and Susan P. Tyler, the University of Cincinnati.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Adams has disclosed no relevant financial relationships with any commercial interest.

Dr. Nabhan:  Employer - Cardinal Health, Inc.;  Stock Ownership - Cardinal Health, Inc.

Dr. Matasar has disclosed no relevant financial relationships with any commercial interest.

Dr. Mato has disclosed no relevant financial relationships with any commercial interest.

Ms. Rogers:  Advisory Board - Gilead Pharmaceuticals; Speakers Bureau - BMS, Jazz Pharmaceuticals, Inc., Seattle Genetics, Teva Pharmacuticals

Ms. Brophy, Ms. Browne, Dr. Callazo, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Mr. Savage, NACCME have disclosed no relevant financial relationships with any commercial interests.

Ms. Forney, Dr. Ricer and Ms. Tyler have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculties have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Grant Support

This activity has been supported through an independent educational grant from Teva Pharmaceuticals.